February 25, 2003
BriteSmile Published in JADA
BriteSmile, a leading international provider of state-of-the-art teeth whitening, today announced that the prestigious Journal of the American Dental Association (JADA) has published a first ever study that confirms the safety and efficacy of light-activated teeth whitening. Significantly, the February issue of the prominent peer reviewed journal used the patented BriteSmile system for its study.
The study also indicated that the BriteSmile procedure contributes to the long-term health of a patient's gums.
The study was completed by the Forsyth Institute, which is one of the world's leading independent organizations dedicated to oral, craniofacial, and related biomedical science. The research was conducted in accordance with ADA clinical research guidelines.
"For years, the dental community has been waiting for independent confirmation of the effectiveness of light-activated teeth whitening," said Dr. Max Goodson, Director of Clinical Research at the Forsyth Institute and the lead researcher on the JADA study.
"This study confirms the benefits of BriteSmile's light-activated one-hour treatment to provide lasting whitening benefits to patients. Publication of the study in a prestigious journal like JADA validates the safety and efficacy of the BriteSmile procedure and marks a major milestone for the company and for cosmetic dentistry in general," added Goodson.
Specifically, the study found that:
* Patients can expect more than eight shades of whitening improvement.
The study found that "on average, the change in tooth color was at
least 8.35 shades of whitening with the peroxide and light
treatment." Significantly, the study also found that "with
additional lighter shade tabs (on the standard measurement guide), an
even greater effect would have been achieved."
* The results are lasting. The study found that whitening results
"should be maintained for 3.6 years."
* The procedure is safe. According to the study, tooth sensitivity was
"mild, transient (vanishing after one week post-treatment) and
primarily associated with peroxide and not light." The BriteSmile
proprietary gel contains a relatively low percentage of hydrogen
peroxide -- 15 percent -- compared to other in-office tooth whitening
options, which use gels that may be comprised of up to 50 percent of
hydrogen peroxide.
* Gum health is improved as a result of the BriteSmile treatment. The
authors of the study were surprised to find that "Gingival Index
measurements significantly decreased over the three- and six-month
periods, suggesting that the tooth-whitening procedure reduced
gingivitis." Other evidence in the study suggests that the
improvement in gingival health was not simply the result of improved
oral care. BriteSmile is currently involved in extensive follow-up
research in the area of oral care with the expectation that it will
develop related products.
* The combination of the light and gel was most effective. According to
the study, the combination of the BriteSmile light and gel "produced
a significantly greater tooth whitening effect than did either light
or peroxide (gel) alone." This finding is significant for many of
the patients and dentists interested in light-based systems.
"The JADA study continues a tradition by BriteSmile of investing in the best technology and ensuring that technology is validated by independent research," said John L. Reed, BriteSmile CEO.
"The study also validates what almost 500,000 people and more than 4,400 dentists around the world have known for some time -- that the BriteSmile system works and is safe and comfortable for the people who choose it," said Reed.
Website: http://www.britesmile.com
Source: BriteSmile
CONTACT: Kelly Sullivan, +1-212-515-1908, or Heather Fass,
+1-212-515-1965, both of BriteSmile
February 19, 2003
Cedara(R) Software chosen by Alara
Cedara Software Corp. (TSX:CDE/NASDAQ:CDSW), a leading independent developer of medical software technologies for the global healthcare market, has signed a development agreement with award-winning Digital Radiography (DR) and Computed Radiography (CR) developer Alara Inc. of Hayward, California.
Under terms of the agreement, Alara Inc. will utilize Cedara's I-Acquire(TM) universal acquisition console application in its new desktop CR unit. I-Acquire enables CR and DR(x) suppliers to acquire images from multiple digital detectors, CR, and x-ray generators, all from a single user interface. The software is unique in providing suppliers with unprecedented flexibility in creating custom-tailored solutions from third-party system components.
"We were looking for a high quality software product from an experienced partner that would lower the development risk and accelerate our time to market, said Dr. Allan Fleischer, President and Chief Executive Officer, Alara Inc. "Cedara I-Acquire meets those needs and provides a number of additional benefits to enhance our CR product line."
I-Acquire features multiple control support, patient demographics, procedure input, intuitive image manipulation tools, and image enhancement algorithms that are automatically applied to optimize each clinical image, as well as much faster throughput for patient exams.
According to Loris Sartor, Vice President of Cedara, "The agreement with Alara positions Cedara as a major player in the desktop CR market. We now have a number of partners that see the universal acquisition capabilities of I-Acquire as essential to building X-ray plates."
About Alara Inc.
Alara Inc. is a privately held medical technology company that develops, manufactures and markets high quality digital imaging products based on storage phosphor technology for medical and dental applications. These instruments include the DenOptix(TM) line of digital dental scanners and the MetriScan(R) bone mineral density screening system. These systems utilize storage phosphor imaging plates to replace film as a radiation detector for image capture. For more information, contact Dr. Allan Fleischer, Alara, Inc., (510) 265-6220. Web site: www.alara.com.
About Cedara Software:
Cedara Software Corp. is a leading independent provider of medical imaging software for many of the world's leading medical devices and healthcare information technology systems companies. Cedara has over 20,000 medical imaging installations worldwide. Cedara's Imaging Application Platform (IAP) software is embedded in 30% of magnetic resonance imaging (MRI) devices in use today. Cedara's Picture Archiving and Communications System (PACS) technology has been installed in over 4,300 global sites.
(x) I-Acquire DR, digital detectors, X-Ray generator control is for use
only as components of a complete medical system solution.
Source: Cedara Software Corp.
CONTACT: Jacques Cornet, Cedara Software Corp., (905) 672-2100 ext.
2564, Email: info@cedara.com, Web site: www.cedara.com;
February 15, 2003
Safety Dental Injector; One-Handed, Single-Use
The Med-Design Corporation (NASDAQ:MEDC) a leader in the design and development of safety needle products for medical use, today announced that the Company has received 510(k) clearance from the Food and Drug Administration for Med-Design's Safety Dental Injector. The Safety Dental Injector is a one-handed, single-use, disposable syringe injector for the delivery of dental anesthetics.
As previously announced, the Safety Dental Injector will be manufactured by Owens-Illinois using equipment designed and owned by Med-Design. Owens- Illinois, based in Toledo, Ohio, is one of the world's leading manufacturers of glass and plastic packaging and medical products.
Med-Design will distribute the Safety Dental Injector through Sultan Chemists (Englewood, NJ), a leader in the field of infection control and oral therapeutics. Sultan, as the exclusive worldwide distributor, will market the product to dentists, dental groups and government institutions through direct channels and established dental retailers.
"FDA 510(k) clearance is a critical step in bringing the Safety Dental Injector to the market," said David Dowsett, Med-Design's Chief Operating Officer. "Because the November 2000 Needlestick Safety and Prevention Act and OSHA's blood borne pathogens standard clearly includes dentistry, many leading dentists have been looking for an effective way to render syringe injectors safe during and after patient use." Dowsett added that "Results of pre- clinical reviews show that dentists favor Med-Design's one-handed operation, which is consistent with current technique, while providing the safety aspect that dentists are seeking."
Upon completion of manufacturing ramp-up at Owens-Illinois, Med-Design and Sultan expect to begin initial shipments to customers in the second quarter 2003.
For more information on Med-Design Corporation you may access the Med- Design Corporation Web site at www.med-design.com.
AT THE COMPANY FOR MEDIA
David Dowsett Michael Simpson Denise Portner
Chief Operating Officer Chief Strategy Officer Tierney Communications
(805) 339-0375 (805) 339-0375 (215) 790-4395
Source: Med-Design Corporation
February 13, 2003
BIOLASE Q4 Earnings
BIOLASE Q4 Earnings of $0.05 on $9.5 Million in Sales
Year End Net Income $2.6 Million on $29.2 Million in Sales
Company Expects Sales Growth of Between 40% to 50% for 2003BIOLASE Technology, Inc. (NASDAQ:BLTI) a medical technology company which develops, manufactures and markets lasers and related products focused on pain-free medical and dental procedures, today reported record sales and earnings for the fourth quarter and year ended December 31, 2002.
Net sales for the fourth quarter of 2002 increased 64% to $9.5 million from $5.8 million in the fourth quarter of 2001. Net sales for the year ended December 31, 2002 were $29.2 million, an increase of 63% over net sales of $17.9 million reported for the year ended December 31, 2001.
Net income for the fourth quarter was $1.1 million or $0.05 per diluted share, compared with $410,000 or $0.02 per diluted share for the fourth quarter of 2001. For the year ended December 31, 2002, net income was $2.6 million or $0.12 per diluted share, compared with a net loss of $408,000 or $0.02 per share for the year ended December 31, 2001.
Jeffrey W. Jones, BIOLASE President and Chief Executive Officer commented, "We continue to solidify our base and produce the corresponding growth in sales and profits, achieving a gross margin of 62.0% and an operating margin of 8.5% for the year. Our sales growth reflects the steadily increasing awareness and acceptance of our Waterlase(R) technology and other products by the dental industry both in the United States and internationally. Yet, only a small fraction of the global market potential has been penetrated by dental laser technology.
"We are focused on delivering state-of-the-art technology and we are increasing our activity to cultivate strategic marketing initiatives to best optimize our outreach and growth opportunities. Our record results reflect the effectiveness of our assertive marketing efforts, including attending conferences and partnering with prestigious dental schools. Overall, our proven technology, marketing prowess and strong sales force directly contribute to BIOLASE's success.
Jones concluded, "As demonstrated by our expanding worldwide presence, record sales and increasing profitability, we have clearly positioned our company to be the leader in dental laser technology. Despite the uncertainties in today's global economic and geopolitical situation, we are forecasting continued strong sales and earnings growth for 2003, with sales increasing between 40% and 50% and gross margin remaining in the 60% range."
Conference Call Information
BIOLASE will host an investment-community conference call to discuss fourth quarter and annual results tomorrow, Thursday, February 13, beginning at 11:30 a.m. EST (8:30 a.m. PST). The conference call will be broadcast live over the Internet at www.biolase.com . Please go to the web site 15 minutes prior to the start of the call to register, download and install the necessary audio software. A replay will be available on the company's web site for seven days.
About BIOLASE
BIOLASE Technology, Inc. ( http://www.biolase.com/ ) is a medical technology company that manufactures and markets advanced dental, cosmetic, aesthetic and surgical laser and related products, including Waterlase(TM) (Hydrokinetic(R)) surgical cutting systems, LaserSmile(TM) and other advanced laser and non-laser products for the medical market. The company's products incorporate patented and patent-pending technologies in the pursuit of painless surgery. BIOLASE is a leading provider of painless hard and soft tissue dental laser technology.
Cautionary Statement
This press release and earnings conference call may contain forward- looking statements that are based on our current expectations, estimates and projections about our industry as well as management's beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include projections about our future earnings and margins and speak only as of the date hereof. Such statements are based upon the information available to us now and are subject to change. We will not necessarily inform you of such changes. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Therefore our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. The important factors which could cause actual results to differ materially from those in the forward-looking statements include, among others, a downturn or leveling off of demand for our products due to the availability and pricing of competing products and technologies, adverse international market or political conditions, a domestic economic recession, the volume and pricing of product sales, our ability to control costs, intellectual property disputes, the effects of natural disasters and other events beyond our control and other factors including those detailed in BIOLASE' filings with the Securities and Exchange Commission including its prior filings on Form 10-K and Form 10-Q.
BIOLASE TECHNOLOGY, INC.
CONSOLIDATED BALANCE SHEETS
December 31,
2002 2001
ASSETS
Current assets:
Cash and cash equivalents $3,940,000 $2,670,000
Accounts receivable, net 4,790,000 2,095,000
Inventories, net 2,792,000 1,887,000
Prepaid expenses and other current assets 876,000 260,000
Total current assets 12,398,000 6,912,000
Property, plant and equipment, net 1,733,000 392,000
Patents and trademarks, net 67,000 91,000
Other assets 197,000 166,000
Total assets $14,395,000 $7,561,000
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Line of credit $1,792,000 $1,792,000
Accounts payable 2,082,000 1,656,000
Accrued liabilities 3,580,000 1,976,000
Customer deposits 329,000 290,000
Deferred gain on sale of building,
current portion 63,000 63,000
Current portion of long-term debt 366,000 --
Total current liabilities 8,212,000 5,777,000
Deferred gain on sale of building 142,000 205,000
Long-term debt 854,000 --
Total liabilities 9,208,000 5,982,000
Stockholders' equity:
Preferred stock, par value $0.001,
1,000,000 shares authorized,
no shares issued and outstanding -- --
Common stock, par value $0.001,
50,000,000 shares authorized;
issued and outstanding -
20,131,000 shares in 2002 and
19,734,000 shares in 2001 20,000 20,000
Additional paid-in capital 49,497,000 48,462,000
Accumulated other comprehensive loss (57,000) --
Accumulated deficit (44,273,000) (46,903,000)
Total stockholders' equity 5,187,000 1,579,000
Total liabilities and
stockholders' equity $14,395,000 $7,561,000
BIOLASE TECHNOLOGY, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
Three Months Ended Twelve Months Ended
December 31 December 31
2002 2001 2002 2001
Net sales $9,495,000 $5,793,000 $29,199,000 $17,887,000
Cost of sales 3,413,000 2,340,000 11,102,000 7,299,000
Gross profit 6,082,000 3,453,000 18,097,000 10,588,000
Operating expenses:
Sales and
marketing 3,612,000 2,144,000 10,922,000 7,421,000
General and
administrative 937,000 475,000 3,010,000 2,011,000
Engineering and
development 536,000 456,000 1,684,000 1,520,000
Total operating
expenses 5,085,000 3,075,000 15,616,000 10,952,000
Income (loss)
from operations 997,000 378,000 2,481,000 (364,000)
Gain on sale of assets 16,000 47,000 63,000 79,000
Gain (loss) on
foreign currency
translation 37,000 -- 51,000 --
Unrealized gain on
forward exchange
contract 50,000 -- 152,000 --
Interest income 5,000 20,000 18,000 44,000
Interest expense (35,000) (35,000) (135,000) (167,000)
Net income
(loss) $1,070,000 $410,000 $2,630,000 $(408,000)
Net income (loss)
per share
Basic $0.05 $0.02 $0.13 $(0.02)
Diluted $0.05 $0.02 $0.12 $(0.02)
Weighted average shares
outstanding
Basic 19,487,260 19,678,000 19,923,000 19,510,000
Diluted 21,755,814 21,138,000 21,637,000 19,510,000
Source: BIOLASE Technology, Inc.
CONTACT: Michael Porter, President, or Christian Pflaumer, V.P./Media
Relations, or Catherine Hay, V.P./Editorial, all of Porter, Le Vay & Rose,
Inc., +1-212-564-4700, for BIOLASE Technology, Inc.; or Jeffrey W. Jones,
President & CEO of BIOLASE Technology, Inc., +1-949-361-1200
Web site: http://www.biolase.com/
February 10, 2003
Plastic To Eliminate Migraine Headaches?
A clinical trial will examine whether a small plastic device will relieve the pain of migraine headache suffers. The Touro College School of Health Sciences and Best-Bite, Inc. announced today a clinical trial to evaluate the response of patients diagnosed with migraines to the Best-Bite Discluder, a small plastic device that assists the jaw joints in centering. The open label clinical trial will examine how the Best-Bite Discluder effects pain levels in migraine headache sufferers, and clarify the relationship between dental occlusion, muscle activity and hyper-activity and migraine headache pain.
"Millions of people are suffering from what they believe are migraine headaches, when in fact they may well be suffering from a bite problem that could be cured," said Dr. Jerry Simon, D.D.S., founder, Best-Bite, Inc and inventor of the Discluder. "We're looking forward to Touro College School of Health Sciences' study as a critical step in our quest to inform both the public and the medical community that the bite does matter."
The Best-Bite Bite Discluder assists in the diagnosis of bite problems, technically referred to as occlusal interference or TMJ-dysfunction. Occlusal interference is a leading cause of head, neck and facial pain (HNFP). An uneven bite can trigger muscle spasms that create tension leading to headaches. Over 45 million Americans suffer HNFP, and most are entirely unaware of the relationship between their bite and their pain. Failure on the part of many non-dental and dental medical practitioners to take proper occlusion into account often leads to misdiagnosis, improper treatment, and unnecessary chronic pain.
Study Details
The study will document the muscle changes that are caused by interposing a thin plastic appliance (Best-Bite Discluder) between the maxillary and mandibular anterior dentition in subjects with migraine headache. Dr. Leonard B. Goldstein, D.D.S, Ph.D., director of the Graduate Program in Forensic Examination, Touro College School of Health Sciences and Medical Director, TMD/Facial Pain Center, Southside Health Institute, Southside Hospital, Bay Shore, NY, will be the principal investigator in the study, set to begin on [date]. The initial study will consist of 30-50 subjects, and a larger study is being planned for the future.
"Over the years there have been multiple theories regarding the underlying physiology of migraine. The premise that nocturnal muscular hyperactivity may be a precursor to migraine, and that an intra-oral device may reduce the intensity of the hyperactivity, thereby reducing migraine frequency, has been observed," said Dr. Goldstein.
How the Best-Bite Discluder Works
The Best-Bite Discluder, acting as the fulcrum, and the muscles, acting as the force, prohibit occlusal interference and allow the condyles to seat in a centered position. Once it is achieved, the muscles no longer need to brace the condyles in an unstable position. The jaw naturally finds a centered position without the biting surfaces of the teeth throwing off jaw joints eliminating muscle spasm pain. The Best-Bite Discluder is the only device that assists in the diagnosis of bite problems.
For more information contact Best-Bite Inc., 888-865-7335, http://www.best-bite.com/ .
CONTACT:
Aakiya Woods/Erika Freed
Ruder Finn
(212) 715-1694/715-1538
Source: Best-Bite, Inc.
CONTACT: Aakiya Woods, +1-212-715-1694, or Erika Freed, +1-212-715-1538,
both of Ruder Finn for Best-Bite, Inc.
Web site: http://www.best-bite.com/
February 7, 2003
Lumenis - New Financing Arrangement
Lumenis Ltd. (NASDAQ:LUME) today announced it reached a new financing arrangement with Bank Hapoalim B. M. The new arrangement extends its existing revolving credit agreement to December 31, 2003, increases the amount available on the revolver to $50 million until July 1, 2003, defers the loan amortization of $10 million principal payment due April 2003 and amends certain covenants in its loan agreements.
Arie Genger, Chief Executive Officer of Lumenis stated, "This important new financing arrangement provides us with the financial flexibility and liquidity we need to complete our cost reductions and implement our inventory reduction program. Total liquidity at December 31, including cash on hand and availability under our new credit agreement, was approximately $27 million."
The company's existing revolving credit agreement of $35 million has been extended from April 30, 2003 to December 31, 2003. Total availability under the revolving credit agreement has been increased by $15 million to $50 million until July 1, 2003, effective December 31, 2002. The interest rate on the $15 million increase will be LIBOR plus 3%. The base rate on the revolver is LIBOR plus 2.25%. At December 31, 2002 approximately $38.9 million was outstanding under the revolver.
Under its term loan agreement, the $10 million semi-annual principal payment due April 2003 has been deferred. Of the deferred amount $5 million will be paid in December 2003 and $5 million in April 2004.
Under its loan agreements, the company is required to maintain a ratio of bank debt to EBITDA, as defined, of less than three times. In November 2002, the company received a waiver of this covenant for the third quarter 2002, and Bank Hapoalim amended the limit to 3.7 times for the fourth quarter ended December 31, 2002. The new amendment waives the requirement for the fourth quarter and replaces the covenant with a minimum EBITDA amount, as defined, for 2003. For the first quarter 2003 the minimum EBITDA is $5 million and for the full year it is required to reach $50 million.
The Company agreed to re-price existing options held by Bank Hapoalim totaling 1.136 million shares to the current market price and to grant an additional 275,000 options at the current market price. The Company will take a charge to earnings for approximately $1 million as the cost of the options. Additionally the Company will pay a $200,000 fee.
Lumenis is currently in the process of recruiting a new permanent Chief Executive Officer.
About Lumenis
Lumenis develops, manufactures, and markets state-of-the-art proprietary laser and intense pulsed light devices. Its systems are used in a variety of aesthetic, ophthalmic, surgical and dental applications, including, hair removal, non-invasive treatment of vascular lesions and pigmented lesions, acne, psoriasis, open angle glaucoma, secondary cataracts, age-related macular degeneration, ENT, gynecology, urinary lithotripsy, benign prostatic hyperplasia, neurosurgery and dentistry. For more information about the Company and its products log on to http://www.lumenis.com/.
The statements in this press release that are not historical facts are forward-looking statements, which are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.
Contacts: Kevin Morano
CFO
212-515-4187
Source: Lumenis Ltd.
CONTACT: Kevin Morano, CFO of Lumenis, +1-212-515-4187
February 6, 2003
BIOLASE Obtains First FDA
BIOLASE Technology, Inc. (NASDAQ:BLTI) , a medical technology company focused on pain-free medical and dental procedures, today announced that it has received clearance from the Food and Drug Administration for the patented Waterlase(TM) system for use in apicoectomy surgery. Apicoectomy surgery, a treatment for root canal infections and complications, includes cutting gum flaps, bone and the apex of the tooth to access the infected area. For more information on apicoectomy surgery, go to www.biolase.com.
Malcom Zola, DDS, Chief, Oral Surgery and Maxillofacial Surgery, St. Barnabus Hospital, New York City, commented, "Use of the Waterlase for apicoectomies is a very significant development in dentistry. Benefits while performing the procedure with the Waterlase, compared to traditional methods, include less bleeding, less trauma, more precision, smoother cuts, more control and superior visibility. Post-operative benefits include reducing or eliminating post-operative pain, inflammation and reducing or eliminating the need for post-op pain medications.
"When using a drill in apicoectomy surgery, adjacent nerves, roots and bone tissues can be damaged. With the Waterlase, we experienced no damage to adjacent tissues. It was easy to use in narrow spaces, caused no charring or burning and we did not have to change surgical tools several times."
Dr. Zola continued, "I expect these important clinical benefits to cause a paradigm shift for both dentists and patients. As the public becomes more aware of the benefits of Waterlase procedures, they will begin demanding them and dentists will now be able to provide them."
Dr. Zola is Board Certified in Oral and Maxillosurgery, and was formerly chairman of Oral Surgery at NOVA South Eastern University, College of Dentistry, Florida.
Dan McEowen, DDS, Frederick, Maryland, with over 20 years of dental surgical experience, commented, "Surgical procedures performed with the Waterlase represent a major advancement for both dentists and patients. This clearance for doing flaps reaches far beyond just apicoectomy surgery. Flap surgery is very common for numerous surgical procedures, including periodontal procedures, implant placement and recovery, extracting wisdom teeth, exposure of impacted teeth for orthodontics, ridge augmentation, access to the bone and more. All of these procedures will benefit from the reduced trauma, pain and improved comfort for the patient both during the procedure and post-operatively."
Jeffrey W. Jones, President and CEO of BIOLASE, noted, "This new clearance, another first in the dental industry, combined with clearances last year for complete root canal and bone procedures, further demonstrates the clinical importance of Waterlase YSGG technology. It makes the Waterlase even more appealing to specialists, such as endodontists, oral surgeons and periodontists as well as general dentists. They can now perform a very wide range of procedures with the Waterlase, from general restorative, all classes of cavity preparations, numerous soft tissue procedures, complete laser root canals, bone and now apicoectomies. This continuing dedication to clinical advancements, research and development will only strengthen our already dominant position in a rapidly expanding market."
About BIOLASE
BIOLASE Technology, Inc. ( http://www.biolase.com/ ) is a medical technology company that manufactures and markets advanced dental, cosmetic, aesthetic and surgical products, including Waterlase Hydrokinetic(TM) surgical cutting systems, LaserSmile(TM) and other advanced laser and non-laser products for the medical market. The Company's products incorporate patented and patent-pending technologies in the pursuit of painless surgery. BIOLASE is a leading provider of painless hard and soft tissue dental laser technology.
This press release and earnings conference call may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management's beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions are intended to identify forward-looking statements. These statements speak only as of the date hereof and are based upon the information available to us now. Such information is subject to change and we will not necessarily inform you of such changes. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Therefore our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.
Source: BIOLASE Technology, Inc.
CONTACT: Michael J. Porter, President/Investor Relations, or Christian
Pflaumer, V.P./Media, both of Porter, Le Vay & Rose, Inc., +1-212-564-4700,
for BIOLASE Technology, Inc.; or Jeffrey W. Jones, President & CEO of BIOLASE
Technology, Inc., +1-949-361-1200
Web site: http://www.biolase.com/